Kyle Casement is VP of Finance at LENZ Therapeutics and has over a decade of experience in finance and accounting, including leadership roles for various IPOs, bond issuances, and mergers and acquisitions.
Prior to joining LENZ, Kyle was Director of Finance, Corporate Controller for PhaseBio Pharmaceuticals, where he helped lead the company through the sale of its assets and winddown of operations. Prior to PhaseBio, he was Associate Director, Reporting and Compliance at BioLegend, where he played a key role on the finance team in the eventual sale of the company to PerkinElmer for $5.25 billion.
Kyle began his career at Moss Adams, where he left as an Assurance Senior Manager in the Technology and Life Sciences practice group providing services to a variety of private and public companies. He also serves as a Board Director for the CSUSM Foundation. He is a Certified Public Accountant and received his Bachelor of Science in Business Administration, Accountancy from California State University San Marcos.